Pfizer (NYSE:PFE) Stock Gets Price Target Boost from Citigroup

Pfizer (NYSE:PFE) had its price target increased by analysts at Citigroup from $27.00 to $30.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup‘s price objective points to a potential downside of 2.58% from the stock’s previous close.

Several other research analysts also recently commented on PFE. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Scotiabank raised their price objective on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Royal Bank Of Canada lifted their target price on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $29.00.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.79 during trading on Wednesday, reaching $30.79. The company had a trading volume of 46,664,040 shares, compared to its average volume of 39,771,121. The stock has a market cap of $175.52 billion, a PE ratio of 40.52, a PEG ratio of 2.08 and a beta of 0.31. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.06. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The business’s 50 day moving average price is $28.64 and its 200-day moving average price is $26.84.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 earnings per share. Analysts expect that Pfizer will post 2.94 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in PFE. Allspring Global Investments Holdings LLC lifted its stake in Pfizer by 11.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,132,291 shares of the biopharmaceutical company’s stock valued at $31,840,000 after purchasing an additional 112,523 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of Pfizer by 62.8% during the third quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock valued at $134,667,000 after buying an additional 1,820,944 shares during the period. Leelyn Smith LLC lifted its stake in Pfizer by 3.9% in the 3rd quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock worth $3,657,000 after purchasing an additional 4,851 shares in the last quarter. Verus Capital Partners LLC raised its position in shares of Pfizer by 5.1% in the third quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 805 shares in the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Pfizer during the 3rd quarter valued at about $221,000. 68.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised 2026 guidance to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Growth is increasingly coming from beyond COVID: non-COVID products grew 7% operationally, while launched and acquired products grew 32%. Eliquis, Padcev and other newer medicines helped support results, strengthening the case that Pfizer’s portfolio can offset pandemic-product weakness. Article: Non-COVID Portfolio Steps Up
• Positive Sentiment: Management is also pursuing growth in obesity medicines, with CEO Albert Bourla saying Pfizer aims to bring its past commercial experience to the weight-loss market. That opportunity could add longer-term upside, though it depends on pipeline and development progress. Article: Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. The appointment provides continuity, but the announcement itself offers limited immediate evidence of a change in financial performance. Article: Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Quarterly revenue was nearly flat year over year as Comirnaty and Paxlovid sales declined sharply. This highlights the continuing challenge of replacing pandemic-era revenue and leaves Pfizer reliant on sustained growth from newer products. Article: Pfizer Q3 Revenue and Product Growth
• Negative Sentiment: Analyst views remain restrained: RBC raised its target to $28 but kept a “sector perform” rating, and J.P. Morgan assigned a “Hold.” RBC’s target is below the cited $30.75 share price, signaling limited upside in its assessment. Article: RBC Raises Pfizer Price Target

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.